Vaccine vials against a generic background

Additional 40 million vaccine doses secured by UK Government

A further 40 million additional doses of the Valneva vaccine candidate have been secured in a new deal signed by the UK Government, helping further bolster the country’s potential vaccine reserves.

The latest deal comes on the back of the UK’s investment into the same firm’s vaccine manufacturing facility in West Lothian, Scotland, which began manufacturing vaccine doses last week and reaffirmed the devolved nation’s role in long-term vaccine production.

With the additional doses secured, the total UK vaccine portfolio now sits at around 407 million doses over the next two years.

The Valneva vaccine candidate is currently going through phase I/II trials and will still need to be approved by the UK regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), as meeting strict requirements on quality, safety and efficacy before it can be rolled out as intended at the end of the year.

If it is approved, manufacturing at risk now will ensure the UK has stocks of the vaccine ready to be rolled out at a much quicker pace.

The decision to purchase the extra 40 million doses is based on the UK strategy to take a wide approach, using different technologies and viral targets to ensure the best chance of securing access to successful vaccines as quickly as possible.

It will also give the UK future flexibility should it need to revaccinate any of the population.

Business Secretary Kwasi Kwarteng said: “This latest deal is yet another weapon in our national arsenal against this terrible disease, and will ensure we have sufficient supplies to protect the British public in 2021 and beyond.

“Backed with major investment from the UK Government, the site in Scotland will be a vaccine production powerhouse, working flat out to ensure we can quickly deploy jabs across the UK if their candidate is approved, while supporting top quality, local jobs.

“Thanks to our incredible UK Vaccine Taskforce, we have now secured a bumper portfolio of over 400 million vaccines, putting our country in an exceptionally strong position to defeat this virus once and for all.”

Vaccines Minister Nadhim Zahawi said: “This deal provides a further boost to the UK’s already-strong vaccine portfolio, and I am enormously proud of all the work which has gone in to securing a vaccine for the UK as soon as possible.

“If approved, the Valneva vaccine will not only help tackle Covid-19 here in the UK, but aid our mission to ensure there is a fair supply of vaccines across the globe.

“No one is safe until the whole world is safe.”

NHE May/June 22

NHE May/June 22

Developing a high-quality NHS estate

The new edition of NHE’s e-magazine highlights the latest in cyber security, pharmaceuticals, NHS workforce, NHS Estates, driving innovation in procurement and more with articles from the likes of Brendan Griffin-Ryan, Senior Category Manager, Estates & Facilities, NHS SBS (pg79), West London NHS Trust and Health Education England.


View all videos
National Health Executive Presents

National Health Executive Presents

NHE365 Virtual Events

NHE has created a full calendar of events to address the most important issues that influence the delivery of healthcare services. Over 365 days you'll have the opportunity to hear from a range of highly motivating, informative and inspirational speakers. These speakers will equip you with the knowledge and unique insight to enable you to overcome the challenges that you face.

Finger on the Pulse

Ep 14. Health messaging is a science, Professor Craig Jackson

On Episode 14 of NHE's Finger on the Pulse podcast, we're joined by Professor Craig Jackson, Professor of Occupational Health Psychology
Birmingham City University to discuss the coronavirus pandemic, the health messaging around it and how those in power have missed a trick by overlooking the key role of psychology in informing the public of restrictions, measures and the ever-changing situation

More articles...

View all